Biomarkers of brain damage in newborns

• Prikhod'ko A.M.
• Anna R. Kirtbaya
• Romanov A.Yu.
• Oleg R. Baev

AbstractIn perinataL medicine, despite Large number evaLuation methods of centraL nervous system (CNS) condition in newborns, it is urgent to search for earLy predictors of brain damage. Identification of CNS damage markers aLLows to evaLuate effectiveness of perinataL asphyxia, hypoxic-ischemic encephaLopathy and intraventricuLar hemorrhages various methods of treatment, and to assess risk of neuroLogicaL impairment. To predict hypoxic trauma consequences, a wide biomarker paneL is studied: neuroproteins, caLcium-binding protein, vasoactive substances, oxidative stress markers, infLammatory mediators. It is known that in case of brain damage, an increase of biomarkers concentration in various bioLogicaL fLuids is observed, degree of which correLates to Lesion severity, regardLess of deLivery date. Thus, the aim of this review is to evaLuate biomarkers roLe in infant brain damage identification and estimation.

Keywords:biomarkers, fetal hypoxia, brain damage

REFERENCES

1. PLeines U.E., Morganti-Kossmann M.C., Rancan M., et aL. S-100 beta reflects the extent of injury and outcome, whereas neuronaL specific enoLase is a better indicator of neuroinfLammation in patients with severe traumatic brain injury. J Neurotrauma. 2001; 18: 491-8.

2. Woertgen C., RothoerL R.D., Metz C., Brawanski A. Comparison of cLin­icaL, radioLogic, and serum marker as prognostic factors after severe head injury. J Trauma. 1999; 47: 1126-30.

3. Hayakata T., Shiozaki T., Tasaki O., et aL. Changes in CSF S100B and cytokine concentrations in earLy-phase severe traumatic brain injury. Shock. 2004; 22: 102-7.

4. Foerch C., Singer O.C., Neumann-HaefeLin T., et aL. EvaLuation of serum S100B as a surrogate marker for Long-term outcome and infarct voLume in acute middLe cerebraL artery infarction. Arch NeuroL. 2005; 62: 1130-4.

5. Sanchez-Pena P., Pereira A.R., Sourour N.A., et aL. S100B as an ad­ditionaL prognostic marker in subarachnoid aneurysmaL hemorrhage. Crit Care Med 2008; 36: 2267-73.

6. Kovesdi E., LuckL J., Bukovics P., et aL. Up-date on protein biomarkers in traumatic brain injury with emphasis on cLinicaL use in aduLts and pedi­atrics. Acta Neurochir (Wien). 2010; 152: 1-17.

7. Moritz S., Schmidt C., Bucher M., et aL. Neuromonitoring in carotid surgery: are the resuLts obtained in awake patients transferabLe to patients under sevofLurane/fentanyL anesthesia? J Neurosurg AnesthesioL. 2010; 22: 21-31.

8. Risso F.M., Sannia A., GazzoLo D. Preterm and term newborn: primary investigations. J Matern FetaL NeonataL Med. 2012; 25: 70-2.

9. HeLLstrom-Westas L., Rosen I. Continuous brain-function moni­toring: state of the art in cLinicaL practice. Semin FetaL NeonataL Med. 2006; 11: 503-11.

10. Kochanek P.M., Berger R.P., Bayir H., et aL. Biomarkers of primary and evoLving damage in traumatic and ischemic brain injury: diagnosis, prognosis, probing mechanisms, and therapeutic decision making. Curr Opin Crit Care. 2008; 14: 135-41.

11. GazzoLo D., AbeLLa R., FrigioLa A., et aL. Neuromarkers and uncon­ventionaL bioLogicaL fluids. J Matern FetaL NeonataL Med. 2010; 23: 66-9.

12. GazzoLo D., AbeLLa R., Marinoni E., et aL. New markers of neonataL neuroLogy. J Matern FetaL NeonataL Med. 2009; 22: 57-61.

13. FLorio P., AbeLLa R., Marinoni E., et aL. BiochemicaL markers of peri­nataL brain damage. Front Biosci (SchoL Ed). 2010; 2: 47-72.

14. GazzoLo D., Di Iorio R., Marinoni E., et aL. S100B protein is increased in asphyxiated term infants deveLoping intraventricuLar hemorrhage. Crit Care Med. 2002; 30: 1356-60.

15. Risso F.M., Serpero L.D., Zimmermann L.J., et aL. PerinataL asphyxia: kidney faiLure does not affect S100B urine concentrations. CLin Chim Acta. 2012; 18: 150-3.

16. GazzoLo D., Marinoni E., Di Iorio R., et aL. Measurement of urinary S100B protein concentrations for the earLy identification of brain damage in asphyxiated fuLL-term infants. Arch Pediatr AdoLesc Med. 2003; 157: 1163-8.

17. CuLLen V.C., Fredenburg R.A., Evans C., et aL. DeveLopment and ad­vanced vaLidation of an optimized method for the quantitation ofAb42 in human cerebrospinaL fLuid. AAPS J. 2012; 14: 510-8.

18. Koo J., Byun Y. Current status of PET-imaging probes of beta-amy­loid plaques. Arch Pharm Res 2013; 36 (10): 1178-84.

19. Apple F.S., Jesse R.L., Newby L.K., et al. National Academy of Clinical Biochemistry; IFCC Committee for Standardization of Markers of Cardiac Damage. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. Circulation. 2007; 115: e352-5.

20. Mulligan J.C., Painter M.J., O'Donoghue P.A., et al. Neonatal as­phyxia II. Neonatal mortality and long-term sequelae. J Pediatr. 1980; 96: 903-7.

21. Low J.A., Lindsay B.G., Derrick E.J. Threshold of metabolic acidosis-associated with newborn complications. Am J Obstet Gynecol. 1997; 177: 1391-4.

22. Gazzolo D., Michetti F. Perinatal S100B protein assessment in­human unconventional biological fluids: a minireview and new perspec­tives. Cardiovasc Psychiatry Neurol. 2010; 2010: 703563.

23. Ferri G.L., Probert L., Cocchia D., et al. Evidence for the presence of S-100 protein in the glial component of the human enteric nervous system. Nature. 1986; 297: 409-10.

24. Pham N., Fazio V., Cucullo L., et al. Extracranial sources of S100B do not affect serum levels. PLoS One. 2010; 5 (9).

25. Blennow M., Savman K., Ilves P., et al. Brain-specific proteins in the cerebrospinal fluid of severely asphyxiated newborn infants. Acta Paediatr. 2001; 90: 1171-5.

26. Gazzolo D., Bruschettini M., Corvino V., et al. S100b protein con­centrations in amniotic fluid correlate with gestational age and with ce­rebral ultrasound scanning results in healthy fetuses. Clin Chem. 2001; 47: 954-6.

27. Gazzolo D., Bruschettini M., Lituania M., et al. S100b protein con­centrations in urine are correlated with gestational age in healthy preterm and term newborns. Clin Chem. 2001; 47: 1132-3.

28. Gazzolo D., Vinesi P., Marinoni E., et al. S100B protein concentra­tions in cord blood: correlations with gestational age in term and preterm deliveries. Clin Chem. 2000; 46: 998-1000.

29. Gazzolo D., Kornacka M., Bruschettini M., et al. Maternal glucocor­ticoid supplementation and S100B protein concentrations in cord blood and urine of preterm infants. Clin Chem. 2003; 4: 1215-8.

30. Sannia A., Risso F.M., Serpero L.D., et al. Antenatal glucocorticoid treatment affects preterm infants' S100B urine concentration in adosedependent manner. Clin Chim Acta. 2010; 411: 1539-41.

31. Gazzolo D., Florio P., Ciotti S., et al. S100B protein in urine of preterm newborns with ominous outcome. Pediatr Res. 2005; 58: 1170-4.

32. Gazzolo D., Frigiola A., Bashir M., et al. Diagnostic accuracy of S100B urinary testing at birth in full-term asphyxiated newborns to predict neonatal death. PLoS One. 2009; 4: e4298.

33. Florio P., Gazzolo D., Luisi S., et al. Activin A in brain injury. Adv Clin Chem. 2007; 43: 117-33.

34. Florio P., Luisi S., Bruschettini M., et al. Cerebrospinal fluid activin a measurement in asphyxiated full-term newborns predicts hypoxic ischemic encephalopathy. Clin Chem. 2004; 50: 2386-9.

35. Florio P., Frigiola A., Battista R., et al. Activin A in asphyxiated full term newborns with hypoxic ischemic encephalopathy. Front Biosci (Elite Ed). 2010; 2: 36-42.

36. Florio P., Luisi S., Moataza B., et al. High urinary concentrations of activin A in asphyxiated full-term newborns with moderate or severe hypoxic ischemic encephalopathy. Clin Chem. 2007; 53: 520-2.

37. Sannia A., Zimmermann L.J., Gavilanes A.W., et al. Elevated activin A urine levels are predictors of intraventricular hemorrhage in preterm newborns. Acta Paediatr. 2013; 102 (10). doi: 10.1111/apa.12332.

38. Florio P., Perrone S., Luisi S., et al. Increased plasma concentrations of activin A predict intraventricular hemorrhage in preterm newborns. Clin Chem. 2006; 52: 1516-21.

39. Bellissima V., Ververs T.F., Visser G.H., Gazzolo D. Selective sero­tonin reuptake inhibitors in pregnancy. Curr Med Chem. 2012; 19: 4554-61.

40. Bellissima V., Visser G.H., Ververs T.F., et al. Antenatal maternal antidepressants drugs affect activin A concentrations in maternal blood, in amniotic fluid and in fetal cord blood. J Matern Fetal Neonatal Med. 2011; 24: 31-4.

41. Di Iorio R., Marinoni E., Lituania M., et al. Adrenomedullinin creases in term asphyxiated newborns developing intraventricular hemor­rhage. Clin Biochem. 2004; 37: 1112-6.

42. Di Iorio R., Marinoni E., Letizia C., et al. Adrenomedullin is in­creased in the fetoplacental circulation in intrauterine growth restriction with abnormal umbilical artery waveforms. Am J Obstet Gynecol. 2000; 182: 650-4.

43. Gazzolo D., Marinoni E., Giovannini L., et al. Circulating adrenomedullin is increased in preterm newborns developing intraventricular hemorrhage. Pediatr Res. 2001; 50: 544-7.

44. Florio P., Luisi S., Bruschettini S., et al. Cerebrospinal fluid activin A measurement in asphyxiated full-term newborns predicts hypoxic ischemic encephalopathy. Clin Chem. 2004; 50: 2386-9.

45. Florio P., Reis F., Severi F., et al. Umbilical cord serum activin A levels are increased in pre-eclampsia with impaired blood flow in the utero-placental and fetal circulation. Placenta. 2006; 27: 432-7.

46. Florio P., Frigiola A., Battista R., et al. Activin A in asphyxiated full-term newborns with hypoxic ischemic encephalopathy. Front. Biosci. 2010; 2: 36-42.

47. Di Iorio R., Marinoni E., Gazzolo D., et al. Maternal nitric oxide sup­plementation increases adrenomedullin concentrations ingrowth retarded fetuses. Gynecol Endocrinol. 2002; 16: 187-92.

48. Florio P., Abella R., Marinoni E., et al. Adrenomedullin blood con­centrations in infants subjected to cardiopulmonary bypass: correlation with monitoring parameters and prediction of poor neurological outcome. Clin Chem. 2008; 54: 202-6.

49. Pahlman S., Esscher T., Bergvall P., Odelstad L. Purification and characterization of human neuron-specific enolase: radioimmunoassay de­velopment. Tumour Biol. 1984; 5: 127-39.

50. Basile A.M., Fusi C., Conti A.A., et al. S-100 protein and neuron specific enolase as markers of subclinical cerebral damage after cardiac surgery: preliminary observation of a 6-month follow-up study. Eur Neurol. 2001; 45: 151-9.

51. Fogel W., Krieger D., Veith M., et al. Serum neuron-specific enolase as early predictor of outcome after cardiac arrest. Crit Care Med. 1997; 25: 1133-8.

52. Garcia-Alix A., Cabanas F., Pellicer A., et al. Neuron-specific enolase and myelin basic protein: relationship of cerebrospinal fluid concentra­tions to the neurologic condition of asphyxiated full-term infants. Pedi­atrics. 1994; 93: 234-40.

53. Celtik C., Acunas B., Oner E., et al. Neuron-specific enolase as a marker of the severity and outcome of hypoxic encephalopathy. Brain Dev. 2004; 26: 398-402.

54. Nagdyman N., Komen W., Ko H., et al. Early biochemical indica­tors of hypoxic ischemic encephalopathy after birth asphyxia. Pediatr Res. 2001; 49: 502-6.

55. Roka A., Kelen D., Halasz J., et al. Serum S100B and neuron-specific enolase levels in normothermic and hypothermic infants after perinatal as­phyxia. Acta Paediatr. 2012; 101: 1184-8.

56. Bracci R., Perrone S., Buonocore G. The timing of neonatal brain damage. Biol Neonate. 2006; 90: 145-55.

57. Perrone S., Tataranno M.L., Stazzoni G., Buonocore G. Biomarkers of oxidative stress in fetal and neonatal diseases. J Matern Fetal Neonatal Med. 2012; 25: 2575-8.

58. Perrone S., Tataranno M.L., Stazzoni G., et al. Oxidative injury in neonatal erythrocytes. J Matern Fetal Neonatal Med. 2012; 25: 104-8.

59. Blennow M., Rosengren L., Jonsson S., et al. Glial fibrillary acidic protein is increased in the cerebrospinal fluid of preterm infants with ab­normal neurological findings. Acta Paediatr. 1996; 85: 485-9.

60. Ennen C.S., Huisman T.A., Savage W.J., et al. Glial fibrillary acidic protein as a biomarker for neonatal hypoxic-ischemic encephalopathytreated with whole-body cooling. Am J Obstet Gynecol. 2011; 205: 251-7.

61. Tenhunen R., Marver H.S., Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA. 1968; 61: 748-55.

62. Denschlag D., Marculescu R., Unfried G., et al. The size of a micro-satellite polymorphism of the haem oxygenase 1 gene is associated with idiopathic recurrent miscarriage. Mol Hum Reprod. 2004; 10: 211-4.

63. Bainbridge S.A., Smith G.N. HO in pregnancy. Free Radic Biol Med. 2005; 38: 979-88.

64. Shrestha Dangol D., Chen H.P. Role of hemeoxygenase-2 in preg­nancy-induced hypertension. Int J Gynaecol Obstet. 2004; 85: 44-6.

65. Barber A., Robson S.C., Myatt L., et al. Heme oxygenase expression in human placenta and placental bed: reduced expression of placenta en­dothelial HO-2 in preeclampsia and fetal growth restriction. FASEB J. 2001; 15: 1158-68.

66. Eide I.P., Isaksen C.V., Salvesen K.A., et al. Decidual expression and maternal serum levels of heme oxygenase 1 are increased in preeclampsia. Acta Obstet Gynecol Scand. 2008; 87: 272-9.

67. Tanaka Y., Maher J.M., Chen C., Klaassen C.D. Hepatic ischemia reperfusion induces renal heme oxygenase-1 via NF-E2-relatedfactor 2 in rats and mice. Mol Pharmacol. 2007; 71: 817-25.

68. Fujita T., Toda K., Karimova A., et al. Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fi­brinolysis. Nat Med. 2001; 7: 598-604.

69. Li Volti G., Galvano F., Frigiola A., et al. Potential immunoregulatory role of heme oxygenase-1 in human milk: a combined biochemical and mo­lecular modeling approach. J Nutr Biochem. 2010; 21: 865-71.

70. Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001; 107: 823-6.

71. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-97.

72. Looney A.-M., et al. Down-regulation of umbilical cord blood levels of miR-374a in neonatal hypoxic ischemic encephalopathy. J. Pediatr. 2015; 167: 269-73.

73. Whitehead C., et al. Quantifying circulating hypoxia-induced RNA transcripts in maternal blood to determine in utero fetal hypoxic status. BMC Med. 2013, 11: 256.

74. Sannia A., Risso F.M., Zimmermann L.J., et al. S100B urine concen­trations in late preterm infants are gestational age and gender dependent. Clin Chim Acta. 2013; 417: 31-4.

75. Serpero L.D., et al. J Matern Fetal Neonatal Med. 2013; 26 (S2): 44-9. Downloaded by [Federal State Institution] at 04:02 11 July 2016.

76. Risso F.M., Serpero L.D., Zimmermann L.J., et al. Urine S100 BB and A1B dimers are valuable predictors of adverse outcome in full-term asphyxiated infants. Acta Paediatr. 2013; 102 (10): e467.

77. Florio P., Marinoni E., Di Iorio R., et al. Urinary S100B protein con­centrations are increased in intrauterine growth-retarded newborns. Pedi­atrics. 2006; 118: e747-54.

78. Florio P., Michetti F., Bruschettini M., et al. Amniotic fluid S100B protein in mid-gestation and intrauterine fetal death. Lancet. 2004; 364: 270-2.

79. Gazzolo D., Serpero L.D., Frigiola A., et al. Antenatal glucocorticoids supplementation and central nervous system development. Curr Drug Metab. 2013; 14: 160-6.

80. Risso F.M., Sannia A., Gavilanes D.A., et al. Biomarkers of brain damage in preterm infants. J Matern Fetal Neonatal Med. 2012; 25: 101-4.

81. Michetti F., Corvino V., Geloso M.C., et al. The S100B protein in bio­logical fluids: more than a lifelong biomarker of brain distress. J Neurochem. 2012; 120: 644-59.

82. Atzori L., Antonucci R., Barberini L., et al. 1H NMR-based metabolomic analysis of urine from preterm and term neonates. Front Biosci (Elite Ed). 2011; 3: 1005-12.

83. Dessi A., Atzori L., Noto A., et al. Metabolomics in newborns with intrauterine growth retardation (IUGR): urine reveals markers of metabolic syndrome. J Matern Fetal Neonatal Med. 2011; 24: 35-9.

84. Roka A., Kelen D., Halasz J., et al. Serum S100B and neuron-specific enolase levels in normothermic and hypothermic infants after perinatal as­phyxia. Acta Paediatr. 2012; 101: 319-23.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)